Morgan Stanley Reiterates Hold Rating for Ironwood Pharmaceuticals (IRWD)

Ironwood Pharmaceuticals (NASDAQ:IRWD)‘s stock had its “hold” rating reiterated by investment analysts at Morgan Stanley in a report released on Monday.

Several other brokerages have also recently weighed in on IRWD. Mizuho reaffirmed a “buy” rating and issued a $20.00 price target (down previously from $23.00) on shares of Ironwood Pharmaceuticals in a research report on Friday, August 25th. Cowen set a $20.00 target price on shares of Ironwood Pharmaceuticals and gave the stock a “buy” rating in a research report on Monday, August 21st. ValuEngine raised shares of Ironwood Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, September 1st. BidaskClub raised shares of Ironwood Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Friday, August 25th. Finally, Credit Suisse Group assumed coverage on shares of Ironwood Pharmaceuticals in a research report on Monday, November 27th. They set a “buy” rating and a $19.00 target price on the stock. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and four have issued a buy rating to the company’s stock. Ironwood Pharmaceuticals currently has an average rating of “Hold” and a consensus target price of $17.88.

Ironwood Pharmaceuticals (NASDAQ:IRWD) opened at $15.80 on Monday. Ironwood Pharmaceuticals has a 1 year low of $13.43 and a 1 year high of $19.94. The company has a debt-to-equity ratio of -22.31, a current ratio of 4.87 and a quick ratio of 4.86.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last announced its quarterly earnings results on Thursday, November 2nd. The biotechnology company reported ($0.18) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.25) by $0.07. Ironwood Pharmaceuticals had a negative net margin of 48.89% and a negative return on equity of 645.22%. The business had revenue of $86.80 million for the quarter, compared to analysts’ expectations of $73.59 million. During the same quarter last year, the firm earned ($0.18) EPS. The firm’s revenue for the quarter was up 31.3% compared to the same quarter last year. analysts forecast that Ironwood Pharmaceuticals will post -1.12 EPS for the current year.

Institutional investors have recently bought and sold shares of the business. Teachers Advisors LLC increased its stake in shares of Ironwood Pharmaceuticals by 2.5% during the 1st quarter. Teachers Advisors LLC now owns 231,163 shares of the biotechnology company’s stock worth $3,944,000 after purchasing an additional 5,567 shares during the last quarter. Renaissance Technologies LLC purchased a new stake in shares of Ironwood Pharmaceuticals during the 1st quarter worth approximately $3,181,000. Aperio Group LLC increased its stake in shares of Ironwood Pharmaceuticals by 11.9% during the 2nd quarter. Aperio Group LLC now owns 13,213 shares of the biotechnology company’s stock worth $249,000 after purchasing an additional 1,410 shares during the last quarter. Russell Investments Group Ltd. increased its stake in shares of Ironwood Pharmaceuticals by 281.9% during the 2nd quarter. Russell Investments Group Ltd. now owns 101,676 shares of the biotechnology company’s stock worth $1,920,000 after purchasing an additional 75,055 shares during the last quarter. Finally, Strs Ohio increased its stake in shares of Ironwood Pharmaceuticals by 63.1% during the 2nd quarter. Strs Ohio now owns 10,600 shares of the biotechnology company’s stock worth $200,000 after purchasing an additional 4,100 shares during the last quarter.

COPYRIGHT VIOLATION NOTICE: This article was originally published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this article on another domain, it was stolen and reposted in violation of international copyright and trademark laws. The original version of this article can be accessed at https://stocknewstimes.com/2017/12/06/morgan-stanley-reiterates-hold-rating-for-ironwood-pharmaceuticals-irwd.html.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc is a biotechnology company. The Company is advancing product opportunities in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC), hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease (uncontrolled GERD), and vascular and fibrotic diseases.

Analyst Recommendations for Ironwood Pharmaceuticals (NASDAQ:IRWD)

Receive News & Ratings for Ironwood Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply